סיטאגמט אס. קיי 1000 מג 50  מג ישראל - עברית - Ministry of Health

סיטאגמט אס. קיי 1000 מג 50 מג

k.s.kim international (sk- pharma) ltd., israel - metformin hydrochloride; sitagliptin - טבליות מצופות פילם - metformin hydrochloride 1000 mg; sitagliptin 50 mg - metformin and sitagliptin

סיטאגמט אס. קיי 850 מג 50  מג ישראל - עברית - Ministry of Health

סיטאגמט אס. קיי 850 מג 50 מג

k.s.kim international (sk- pharma) ltd., israel - metformin hydrochloride; sitagliptin - טבליות מצופות פילם - metformin hydrochloride 850 mg; sitagliptin 50 mg - metformin and sitagliptin

סיטאפורמין טבע 50 מג1000 מג ישראל - עברית - Ministry of Health

סיטאפורמין טבע 50 מג1000 מג

teva israel ltd - metformin hydrochloride; sitagliptin as malate - טבליות מצופות פילם - metformin hydrochloride 1000 mg; sitagliptin as malate 50 mg - metformin and sitagliptin

סיטאפורמין טבע 50 מג500 מג ישראל - עברית - Ministry of Health

סיטאפורמין טבע 50 מג500 מג

teva israel ltd - metformin hydrochloride; sitagliptin as malate - טבליות מצופות פילם - metformin hydrochloride 500 mg; sitagliptin as malate 50 mg - metformin and sitagliptin

סיטאפורמין טבע 50 מג850 מג ישראל - עברית - Ministry of Health

סיטאפורמין טבע 50 מג850 מג

teva israel ltd - metformin hydrochloride; sitagliptin as malate - טבליות מצופות פילם - metformin hydrochloride 850 mg; sitagliptin as malate 50 mg - metformin and sitagliptin

סיטאמין טבע 50 מג 1000 מג ישראל - עברית - Ministry of Health

סיטאמין טבע 50 מג 1000 מג

teva israel ltd - metformin hydrochloride; sitagliptin as phosphate - טבליות מצופות פילם - sitagliptin as phosphate 50 mg; metformin hydrochloride 1000 mg - metformin

סיטאמין טבע 50 מג 500 מג ישראל - עברית - Ministry of Health

סיטאמין טבע 50 מג 500 מג

teva israel ltd - metformin hydrochloride; sitagliptin as phosphate - טבליות מצופות פילם - sitagliptin as phosphate 50 mg; metformin hydrochloride 500 mg - metformin

בינוקריט 1000 יחבל 0.5 מל ישראל - עברית - Ministry of Health

בינוקריט 1000 יחבל 0.5 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

בינוקריט 2000 יחבל 1 מל ישראל - עברית - Ministry of Health

בינוקריט 2000 יחבל 1 מל

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob